alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
II 

Calendar No. 109 

118TH CONGRESS 

1ST SESSION S. 1214 

To set forth limitations on exclusive approval or licensure of drugs designated 

for rare diseases or conditions. 

IN THE SENATE OF THE UNITED STATES 

APRIL 19, 2023 

Ms. BALDWIN (for herself and Mr. BRAUN) introduced the following bill; 

which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

JUNE 22, 2023 

Reported by Mr. SANDERS, without amendment 

A BILL 

To set forth limitations on exclusive approval or licensure 

of drugs designated for rare diseases or conditions. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Retaining Access and 

5 Restoring Exclusivity Act’’ or the ‘‘RARE Act’’. 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•S 1214 RS

1 SEC. 2. LIMITATIONS ON EXCLUSIVE APPROVAL OR LICEN2 SURE OF ORPHAN DRUGS. 

3 (a) IN GENERAL.—Section 527 of the Federal Food, 

4 Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended— 

5 (1) in subsection (a), in the matter following 

6 paragraph (2), by striking ‘‘same disease or condi7 tion’’ and inserting ‘‘same approved use or indica8 tion within such rare disease or condition’’; 

9 (2) in subsection (b)— 

10 (A) in the matter preceding paragraph (1), 

11 by striking ‘‘same rare disease or condition’’ 

12 and inserting ‘‘same approved use or indication 

13 for which such 7-year period applies to such al14 ready approved or licensed drug’’; and 

15 (B) in paragraph (1), by inserting ‘‘, relat16 ing to the approved use or indication,’’ after 

17 ‘‘the needs’’; 

18 (3) in subsection (c)(1), by striking ‘‘same rare 

19 disease or condition as the already approved drug’’ 

20 and inserting ‘‘same use or indication for which the 

21 already approved or licensed drug was approved or 

22 licensed’’; and 

23 (4) by adding at the end the following: 

24 ‘‘(f) APPROVED USE OR INDICATION DEFINED.—In 

25 this section, the term ‘approved use or indication’ means 

26 the use or indication approved under section 505 of this 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

•S 1214 RS

1 Act or licensed under section 351 of the Public Health 

2 Service Act for a drug designated under section 526 for 

3 a rare disease or condition.’’. 

4 (b) APPLICATION OF AMENDMENTS.—The amend5 ments made by subsection (a) shall apply with respect to 

6 any drug designated under section 526 of the Federal 

7 Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), regard8 less of the date on which the drug was so designated, and 

9 regardless of the date on which the drug was approved 

10 under section 505 of such Act (21 U.S.C. 355) or licensed 

11 under section 351 of the Public Health Service Act (42 

12 U.S.C. 262). 


pbinns on DSKJLVW7X2PROD with $$_JOB
Calendar No. 109 

118TH CONGRESS 

1ST SESSION S. 1214 

A BILL 

To set forth limitations on exclusive approval or liconditions. censure of drugs designated for rare diseases or 

JUNE 22, 2023 

Reported without amendment 


pbinns on DSKJLVW7X2PROD with $$_JOB
***CERTIFICATION        PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED***

***PURSUANT        TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002***

|   | (1) | The                  Report fully complies with the requirements of Section 13(a) or                  15(d) of                  the Securities Exchange Act of 1934;                  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The                  information contained in the Report fairly presents, in all material                  respects, the financial condition and results of operations of                  the                  Company. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| /s/ Mark                  Klein                                                                                                                                                                                    |
| Name: Mark                  KleinTitle:   Chief                  Executive Office, President and Director(Principal                  Executive Officer) Date:                  April 29, 2008  |
|                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                    |
| /s/ Deborah                  A. Gargiulo                                                                                                                                                                           |
| Name: Deborah                  A. GargiuloTitle:   Chief                  Financial Officer(Principal                  Financial and Accounting Officer) Date:                  April 29, 2008 |

----
Fourth Court of Appeals

San Antonio, Texas

August 25, 2021 

No. 04-21-00031-CV

IN THE INTEREST OF C.C., A CHILD

From the 45th Judicial District Court, Bexar County, Texas 

Trial Court No. 2019-PA-01368 

Honorable Martha Tanner, Judge Presiding 

ORDER

This is an appeal of an order terminating appellant’s parental rights. On July 28, 2021, we 

issued an opinion and judgment affirming the trial court’s order, and on August 16, 2021, we 

denied appellant’s pro se motion for rehearing. Accordingly, the current deadline for appellant to 

file a petition for review in the Supreme Court of Texas is September 30, 2021. See TEX. R. APP.

P. 53.7 (petition for review is due within 45 days of “the date of the court of appeals’ last ruling

on all timely filed motions for rehearing or en banc reconsideration”).

 On August 19, 2021, appellant’s appointed counsel filed a motion to withdraw. The only 

reason stated in counsel’s motion is that appellant asked him to withdraw. While appellant’s pro 

se motion for rehearing confirms she asked appointed counsel to withdraw, the only reason 

stated is that counsel “did not request oral argument” and “was negligent in communication with 

me,” with no further details.

The Supreme Court of Texas has held that appointed counsel’s duty to his client in a 

parental termination appeal is not complete until the filing of a petition for review in that court. 

In re P.M., 520 S.W.3d 24, 27 (Tex. 2016). “Once appointed by the trial court, counsel should be 

permitted to withdraw only for good cause . . . . Mere dissatisfaction of counsel or client with 

each other is not good cause.” Id.

It appears from the limited information we have that counsel and appellant are merely 

dissatisfied with each other. Because appellant has a right to appointed counsel through the filing 

of a petition for review, allowing counsel to withdraw would require an abatement of this appeal 

and a remand to the trial court for appointment of new counsel. See id. at 27–28. However, 

because appellant’s petition for review deadline is imminent, we conclude such an abatement 

would “result in foreseeable prejudice to the client.” See id. at 27; see also City of San Antonio v. 

Hartman, 201 S.W.3d 667, 669–70 (Tex. 2006) (analyzing whether petition for review was 

timely filed so as to invoke supreme court’s jurisdiction). We therefore DENY counsel’s motion 

to withdraw. 
It is so ORDERED on August 25, 2021. 

 PER CURIAM

ATTESTED TO: /s/ Michael A. Cruz

 Michael A. Cruz, 

 Clerk of Court
Trevor DAVIS, Appellant/Petitioner(s), v. In re FORFEITURE OF: $15,263.22 IN U.S. CURRENCY, Appellee/Respondent(s).

CASE NO.: 2D16-4725

District Court of Appeal of Florida, Second District.

July 07, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Granted. Dismissed.
[Federal Register Volume 74, Number 66 (Wednesday, April 8, 2009)]
[Notices]
[Page 16012]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-7970]


-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Proposal Review Panel for Materials Research; Notice of Meeting

    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463 as amended), the National Science Foundation announces the 
following meeting:

    Name: Facility Operations Review Panel of the Division of 
Materials Research (1203).
    Dates & Times: April 27, 28, 29, 2009.
    Place: Cornell University, Ithaca, NY.
    Type of Meeting: Part-open.
    Contact Person: Dr. Guebre X. Tessema, Program Director, 
National Facilities Programs, Division of Materials Research, Room 
1080, National Science Foundation, 4201 Wilson Boulevard, Arlington, 
VA 22230, Telephone (703) 292-4935.
    Purpose of Meeting: To provide advice and recommendations 
concerning operations of the Cornell High Energy Synchrotron Source 
(DMR) <greek-i> 0936384.

Agenda:

Monday, April 27

7 p.m.-8:30 p.m. Closed--Working Dinner and Executive Session.

Tuesday, April 28

8 a.m.-11:45 a.m. Open--CHESS Overview and Presentations by 
Principal Investigator and staff, Proposed Scientific Initiatives I.
11:45 a.m.-12:15 p.m. Closed--Executive Session.
12:15 p.m.-4:30 p.m. Open--Lunch with graduate students, tour of 
facilities, Presentations by Principal Investigator and staff, 
Proposed Scientific Initiatives II.
8 p.m.-10 p.m. Executive Session.

Wednesday, April 29

8 a.m.-3 p.m. Closed--Executive Sessions and report writing.
    Reason for Closing: The work being reviewed may include 
information of a proprietary or confidential nature, including 
technical information; financial data, such as salaries and personal 
information concerning individuals associated with the proposals. 
These matters are exempt under 5 U.S.C. 552b(c), (4) and (6) of the 
Government in the Sunshine Act.

Susanne Bolton,
Committee Management Officer.
[FR Doc. E9-7970 Filed 4-7-09; 8:45 am]
BILLING CODE 7555-01-P
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 1085 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                S. 1085

    To provide authorization for nonpecuniary damages in an action 
    resulting from a cruise ship voyage occurring on the high seas.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             March 30, 2023

Mrs. Fischer (for herself and Mr. Blumenthal) introduced the following 
 bill; which was read twice and referred to the Committee on Commerce, 
                      Science, and Transportation

_______________________________________________________________________

                                 A BILL

 
    To provide authorization for nonpecuniary damages in an action 
    resulting from a cruise ship voyage occurring on the high seas.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hammers' Law''.

SEC. 2. LIMITATIONS IN CERTAIN CASES.

    (a) In General.--Section 30307 of title 46, United States Code, is 
amended--
            (1) in the section heading, by striking ``Commercial 
        aviation accidents'' and inserting ``Limitations in certain 
        cases'';
            (2) by striking subsection (a) and inserting the following:
    ``(a) Definitions.--In this section:
            ``(1) Cruise ship.--The term `cruise ship' means a 
        passenger vessel, other than a vessel of the United States 
        operated by the Federal Government or a vessel owned and 
        operated by a State, that--
                    ``(A) is authorized to carry at least 250 
                passengers;
                    ``(B) has onboard sleeping facilities for each 
                passenger;
                    ``(C) is on a voyage that embarks or disembarks 
                passengers in the United States; and
                    ``(D) is not engaged on a coastwise voyage.
            ``(2) Nonpecuniary damages.--The term `nonpecuniary 
        damages' means damages for loss of care, comfort, and 
        companionship.'';
            (3) in subsection (b), by inserting ``or cruise ship 
        voyage'' after ``commercial aviation''; and
            (4) in subsection (c), by inserting ``or cruise ship 
        voyage'' after ``commercial aviation''.
    (b) Clerical Amendment.--The table of sections for chapter 303 of 
title 46, United States Code, is amended by striking the item relating 
to section 30307 and inserting the following:

``30307. Limitations in certain cases.''.
                                 <all>
```
Lee KALLETT, Appellant/Petitioner(s), v. Sheryl KASTRINER, Appellee/Respondent(s).

CASE NO.: 2D17-1255

District Court of Appeal of Florida, Second District.

October 09, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 10-6884

UNITED STATES OF AMERICA,

 Plaintiff – Appellee,

v.

SHEROD MAIR,

 Defendant - Appellant.

Appeal from the United States District Court for the Eastern 

District of North Carolina, at Raleigh. W. Earl Britt, Senior

District Judge. (5:99-mj-00210-BR-1; 5:10-cv-00222-BR)

Submitted: May 23, 2011 Decided: June 3, 2011

Before MOTZ, KING, and WYNN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Sherod Mair, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Sherod Hastings Mair seeks to appeal the district 

court’s order denying relief on his 28 U.S.C.A. § 2255 (West 

Supp. 2010) motion. The order is not appealable unless a 

circuit justice or judge issues a certificate of appealability. 

28 U.S.C. § 2253(c)(1) (2006). A certificate of appealability 

will not issue absent “a substantial showing of the denial of a 

constitutional right.” 28 U.S.C. § 2253(c)(2) (2006). When the 

district court denies relief on the merits, a prisoner satisfies 

this standard by demonstrating that reasonable jurists would 

find that the district court’s assessment of the constitutional 

claims is debatable or wrong. Slack v. McDaniel, 529 U.S. 473, 

484 (2000); see Miller-El v. Cockrell, 537 U.S. 322, 336-38 

(2003). When the district court denies relief on procedural 

grounds, the prisoner must demonstrate both that the dispositive 

procedural ruling is debatable, and that the motion states a 

debatable claim of the denial of a constitutional right. Slack, 

529 U.S. at 484-85. We have independently reviewed the record 

and conclude that Mair has not made the requisite showing. 

Accordingly, we deny a certificate of appealability and dismiss 

the appeal. We dispense with oral argument because the facts 

and legal contentions are adequately presented in the materials 
3

before the court and argument would not aid the decisional 

process.

DISMISSED
# C_2011358EN.01000601.xml

| 8.12.2011 | EN | Official Journal of the European Union | C 358/6 |
| --- | --- | --- | --- |

8.12.2011

EN

Official Journal of the European Union

C 358/6

---

Non-opposition to a notified concentration

(Case COMP/M.6427 — Hermes Europe/Armadillo Holding/B2C)

(Text with EEA relevance)

2011/C 358/03

On 2 December 2011, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6427. EUR-Lex is the on-line access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/en/index.htm) under document number 32011M6427. EUR-Lex is the on-line access to the European law.

---
Jose Oscar DUQUE, Appellant, v. The STATE of Florida, Appellee.

No. 3D16-2533

District Court of Appeal of Florida, Third District.

Opinion filed March 28, 2018

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
BINGHAM PARTNERS, L.P.
                      c/o Insignia Financial Group, Inc.
                         One Insignia Financial Plaza
                                 P.O. Box 1089
                            Greenville, S.C.  29602

                                 June 3, 1997

VIA FACSIMILE

Labroc II Limited Partnership
and
Labroc III Limited Partnership
c/o The Balcor Company
Bannockburn Lake Office Plaza
2355 Waukegan Road, Suite A 200
Bannockburn, Illnois  60015

     Re:  Acquisition of Bingham IV and Bingham V, Bingham Farms, Michigan

Gentlemen:

     Reference is hereby made to the following:  (i) that certain Agreement of
Sale dated May 2, 1997, made by and between Bingham Partners, L.P. ("Buyer")
and Labroc II Limited Partneship and (ii) that certain Agreement of Sale dated
May 2, 1997, made by and between Buyer and Labroc III Limited Partnership with
respect to acquisition of the above referenced premises (collectively, the
"Purchase Agreement")  Capitalized terms not otherwise defined shall such
meaning as set forth in the Purchase Agreement.

     Please be advised that Buyer has retained our firm as special counsel in
this matter.  Accordingly, we hereby request, on behalf of Buyer, that the
Inspection Period by extended to the end of business June 18, 1997.

     If the foregoing is acceptable, please execute and return one copy of this
letter.  This letter may be executed in counterparts, each of which when so
executed and delivered shall constitute but one and the same instrument.

                         BINGHAM PARTNERS, L.P.

                         By:  ICIG Bingham, LLC, its general partner

                              By:  Insignia Commercial Investments
                                   Group, Inc., its manager

                                By:   /s/ Jeffrey Goldberg
                                     --------------------------------
                                Name:     Jeffery Goldberg
                                     --------------------------------
                                Title:    Vice President
                                     --------------------------------
<PAGE>
ACCEPTED AND AGREED TO:

LABROC II LIMITED PARTNERSHIP

By:  Balcor Equity Partners-II, its general partner

     By:  The Balcor Company, its general partner

          By:   /s/ Alan E. Muench
               ----------------------------------
          Name:     Alan E. Muench
               ----------------------------------
          Title:    Authorized Agent
               ----------------------------------


LABROC III LIMITED PARTNERSHIP

By:  Balcor Equity Partners-III, its general partner

     By:  The Balcor Company, its general partner

          By:   /s/ Alan E. Muench
               ----------------------------------
          Name:     Alan E. Muench
               ----------------------------------
          Title:    Authorized Agent
               ----------------------------------

cc:  Robert G. Koen, Esq.
     Kyle Hauberg, Esq.
<PAGE>
**EXHIBIT      32.1**

**CERTIFICATION      PURSUANT TO**

**18      U.S.C. SECTION 1350,**

**AS      ADOPTED PURSUANT TO**

**SECTION      906 OF THE SARBANES-OXLEY ACT OF 2002**

|  | (1) | The                Report fully complies with the requirements of  Section 13(a)                or 15(d) of the Securities Exchange Act of 1934;                and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The                information contained in the Report fairly presents, in all material                respects, the financial condition and results of operations of the                Company. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   | /s/                Kenneth M. Ferry    |
|--------|--------|----------------------------------------|
|        |   | Kenneth                M. Ferry        |
|   |   | Chief                Executive Officer |

----
Luis GONZALEZ-NIEVES, Appellant, v. STATE of Florida, Appellee.

Case No. 5D17-91

District Court of Appeal of Florida, Fifth District.

Decision filed January 30, 2018

**DECISION WITHOUT PUBLISHED OPINION**

AFFIRMED.
### IN THE

TENTH COURT OF APPEALS

No. 10

- 14

- 00237

- CV

MARY ALICE EMANUEL,

ERVIN MITCHEL EMANUE L,

SHIRLEY ANN RIVERS

, JAMES EDWARD EMANUEL,

ROY LEONARD EMANUEL,

CLAUDIA FAY HASHEMI, AND

EVELYN M. DUPLESSIS

Appellant

v.

DARRELL EARL EMANUEL AND

CEDRIC ROYDELL EMANEUL,

Appellee

From the 87th District Court

Leon County, Texas

Trial Court No. 0

- 10

- 465

O R D E R T O S H O W C A U S EIT IS ORDERED that Helen C. Wooten appear before this Court in the

courtroom of the Tenth Court of Appeals, 501 Washington Avenue, Room 404, Waco,

McLennan County, Texas, at 10:00 a .m., on Monday , April 1 3 , 2015, to show cause and

explain her delay in filing the reporter’s record in the above cause.

SIGNED Mar ch 19 , 2015.

CHIEF JUSTICE PRESIDING
# Europeiska unionens C 38I/2021

| | ISSN 1977-1061 |
| --- | --- |
| Europeiska unionens
  officiella tidning | C 038I |
| | |
| Svensk utgåva | Meddelanden och upplysningar | 64 årgången3 februari 2021 |

ISSN 1977-1061

Europeiska unionens

officiella tidning

C 038I

Svensk utgåva

Meddelanden och upplysningar

64 årgången3 februari 2021

---

| Innehållsförteckning | Sida |
| --- | --- |
| | V   Yttranden |
| | ADMINISTRATIVA FÖRFARANDEN |
| | Rådet |
| 2021/C 38 I/01 | Meddelande om annullering | 1 |

Innehållsförteckning

Sida

V   Yttranden

ADMINISTRATIVA FÖRFARANDEN

Rådet

2021/C 38 I/01

Meddelande om annullering

1

---

| SV | |
| --- | --- |

SV

---

V Yttranden

ADMINISTRATIVA FÖRFARANDEN

Rådet

| 3.2.2021 | SV | Europeiska unionens officiella tidning | CI 38/1 |
| --- | --- | --- | --- |

3.2.2021

SV

Europeiska unionens officiella tidning

CI 38/1

---

MEDDELANDE OM ANNULLERING

(2021/C 38 I/01)

Härmed annulleras det meddelande om Utlysning av ledig tjänst, CONS/AD/167/21, som offentliggjorts i Europeiska unionens officiella tidning (1)

---

(1)  EUT C 29 A, 26.1.2021, s. 1.

---
David A. VELASCO, Appellant/Petitioner(s), v. STATE of Florida, Appellee/Respondent(s).

CASE NO.: 2D17-2639

District Court of Appeal of Florida, Second District.

August 04, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Dismissed.